Ambrosia Biosciences Hires Obesity Specialist as Chief Medical Officer
4 Articles
4 Articles
The country's largest pharmaceutical group, Novo Nordisk, is now hitting new records in its Russian business after a couple of years of depressed results. Tax returns for Novo Nordisk's Russian subsidiary show...
Ambrosia Biosciences hires obesity specialist as chief medical officer
Shapiro Manning, who, according to a news release from the Boulder drug-discovery company, “brings nearly three decades of leadership in obesity and cardiometabolic disease clinical care and research,” has held leadership roles with Novo Nordisk, Boehringer Ingelheim and Rhythm Pharmaceuticals.
Billion-Dollar Markets of Obesity, Oncology, and Neurology in Focus: Novo Nordisk, Vidac Pharma, and AbbVie
Novo Nordisk: Driving the Weight-Loss Pill Forward Recent developments at Novo Nordisk paint a picture of a company caught between conflicting forces. On the one hand, the European Commission approved the Wegovy tablet in mid-July, marking a significant milestone in the rapidly growing market for oral GLP-1 therapies. On the other hand, the company suffered a setback in February. Its Phase III trial of the combination therapy CagriSema failed to…
It was published in the Official Gazette No 173 of 28 July 2026 the decree of the Minister of Health of 19 June 2026 defining the composition of the Observatory for the Study of Obesity (OSO), established at the Ministry of Health by Article 4 of the Law of 3 October 2025, n. 149. The decree, signed by Minister Orazio Schillaci, implements the law that recognizes obesity as a progressive and recurrent disease and which authorised an expenditure …
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
